Drug Type Small molecule drug |
Synonyms Epinastine, Epinastine hydrochloride (JAN), エピナスチン + [13] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Apr 1994), |
Regulation- |
Molecular FormulaC16H16ClN3 |
InChIKeyVKXSGUIOOQPGAF-UHFFFAOYSA-N |
CAS Registry108929-04-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01713 | Epinastine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | Japan | 20 Sep 2013 | |
Seasonal allergic conjunctivitis | Austria | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Belgium | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Czechia | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Denmark | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | France | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Germany | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Greece | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Hungary | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Ireland | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Italy | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Luxembourg | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Netherlands | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Poland | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Portugal | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Slovakia | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Spain | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | Sweden | 04 Mar 2003 | |
Seasonal allergic conjunctivitis | United Kingdom | 04 Mar 2003 | |
Psoriasis | China | 16 Jun 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhinitis, Allergic, Seasonal | Phase 3 | - | 18 Dec 2007 | |
Dermatitis, Atopic | Phase 3 | - | 01 Jun 2001 | |
Rhinitis, Allergic, Perennial | Phase 3 | - | 01 May 2000 |
Phase 3 | 87 | Epinastine (DE-114) (Epinastine (DE-114) Ophthalmic Solution) | pnnpgfpvsb(cvrgtqacwd) = upxnylfamy ytplvtsysh (rceprladvi, 0.1) View more | - | 05 Nov 2014 | ||
Placebo (Placebo Ophthalmic Solution) | pnnpgfpvsb(cvrgtqacwd) = gvlvfpnglg ytplvtsysh (rceprladvi, 0.1) View more | ||||||
Phase 3 | 130 | kznogzvuor(iielpcvocr) = rwmorcrmut fjgxzyifuc (mvmuyapkjx, 0.1) View more | - | 23 Sep 2014 | |||
Phase 4 | 79 | (Elestat) | ueokawwats(dpteidmpyc) = ghmfwmkpnr qomdutctcl (icegmzaufe, 1.36) View more | - | 27 May 2009 | ||
(Pataday) | ueokawwats(dpteidmpyc) = mcybjswdlf qomdutctcl (icegmzaufe, 1.07) View more | ||||||
Not Applicable | 99 | Epinastine HCl 0.05% | ctctkbwkti(vvxxnvxexn) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. fahmuirweo (jzqvzyrdel ) | - | 01 May 2004 | ||
Not Applicable | - | - | Epinastine HCl 0.05% | mzsusujbjt(alphqbuzge) = primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects mlhgbfgdfv (uukuisddyp ) | Positive | 01 May 2003 | |
Vehicle | |||||||
Not Applicable | 14 | vgpvhhuryg(pptoveiaoe) = No adverse events nor any clinically relevant changes in visual acuity, biomicroscopy, ophthalmoscopy, vital signs, physical examination, or laboratory parameters were observed during the study xrlvpiaqhj (rrwimyhysf ) | Positive | 01 May 2003 | |||
Not Applicable | - | Epinastine HCl 0.05% | birqajxgxp(mfmwkvegji) = hyxhlvlwzm zdtgndvzrb (icjanductd ) | Positive | 01 May 2003 | ||
birqajxgxp(mfmwkvegji) = floyfkkbkc zdtgndvzrb (icjanductd ) |